15 years of blood, sweat and tears now paying dividends
15 years of blood, sweat and tears now paying dividends
General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.
About this video
Imricor (IMR) CEO Steve Wedan says the past 12 months have been monumental for the company, despite COVID headwinds. The company added five new sites in Europe, brining the total to 14. The company also successfully raised $16.5M dollars to execute its strategic plan which includes growing its installed base, expanding geographies and expanding its indications. US regulatory approval has always been a hinderance, but Steve explains early commercialisation in Europe was all part of the a cooperative research and development agreement. Imricor is now working with the FDA on an investigational device exemption, which is currently in a review process, and is a precursor to clinical trials. Steve anticipates FDA approval will come in 2023. Listen to Steve's take on whether Imricor is a takeover target, and whether he would bite. Shares in the medtech company moved higher in early Thursday trade on the news.
More like this
4:05
Market Update | Corporate Travel Management, Santos, Vault Minerals, Kingsgate Consolidated, Vulcan Energy, Imricor Medical Systems, PYC Therapeutics3 Sept 2026 · CTD, STO, VAU54:27
the callthe call: Friday May 30th | PTN FND TUA TWR CMW MVF IMR MYX ALX30 May 2025 · 360, ALX7:16
Three fallen ASX angels21 Jan 2022 · PRN4:22
Imricor inks deal with Massachusetts' MiRTLE Medical29 Sept 2021